Research & Development Overview

NeoStem, a biopharmaceutical company developing novel cell based personalized medicine therapies, has a robust, diversified pipeline based on proprietary technologies. We invite you to learn more about our investigational cell therapeutics and future development of these technologies.


Metastatic melanoma

Targeting cancer initiating cells

NeoStem is developing an immunotherapeutic applicable across multiple solid tumors with Special Protocol Assessment, Fast Track and Orphan Drug designations for a Phase 3 program in metastatic melanoma and near-term development milestones.

Learn More


Acute myocardial infarction – STEMI

Enhancing the body’s healing response

NeoStem is developing a cell therapeutic applicable for multiple cardiovascular indications with an ongoing Phase 2 study for acute myocardial infarction.

Learn More


Type 1 diabetes

Rebalancing the immune system

NeoStem is developing an immunomodulation therapeutic platform targeting type 1 diabetes and other autoimmune disorders.

Learn More

NeoStem - Cell Therapy Development - Clinical